Roctavian
Overview
Commercial U.S. availability ended May 2026; not an FDA safety withdrawal
- Generic name
- valoctocogene roxaparvovec-rvox
- Product class
- Gene therapy (AAV5, FVIII)
- Conditions
- Severe hemophilia A (adults)
- Route
- IV one-time
Important safety information
Use official prescribing information and your care team for treatment decisions. This directory gives no dosing advice or medication prices.
Side-effect reports go directly to the FDA, the manufacturer and your HTC. HemoLife Social never receives or stores them. In an emergency, call your local emergency number.
Member experiences
Reviews and community posts are visible only to signed-in members.
Sign in to connectRelated listings
Sources
Imported: 2026-10-26 · Individual verification pending
- https://www.bleeding.org/healthcare-professionals/guidelines-on-care/products-licensed-in-the-us
- https://bleedingdisordersnc.org/the-who-what-guide/
- https://www.fda.gov/vaccines-blood-biologics/roctavian
- https://www.bleeding.org/sites/default/files/document/files/MASAC-Products-Licensed.pdf
- https://www.bleeding.org/news/biomarin-pulls-roctavian-hemophilia-a-gene-therapy-from-us-market